The rate of relapse among patients with TP53-mutated myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) was similar among those who underwent allogeneic hematopoietic stem cell transplant ...
Venclexta-based regimens showed survival benefits in AML and MDS, with a two-year overall survival rate of 46% and median survival of 18.73 months. Remission was achieved by 57.1% of AML patients and ...
The blood cancers acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are extremely challenging to treat. While advances in immunotherapy have cured many patients with other blood cancers, ...
GRAFAPEX™ (treosulfan) with fludarabine is FDA-approved for AML and MDS patients undergoing alloHSCT, showing improved overall survival compared to busulfan. Common side effects include ...
The FDA approved treosulfan (Grafapex) with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation in patients ages 1 year and older with acute myeloid leukemia ...
Investigators say a better understanding of risk factors and categories can help personalize care for patients living with myelodysplastic syndrome (MDS). Men, patients with low absolute neutrophil ...
Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. So, in terms of preventing MDS, that's a ...
Innovative models of germline genetic evaluation are needed for patients with MDS/AML to address systems-level barriers to care, including the development of inpatient genetic counseling and testing ...
Bristol-Myers Squibb Company ((BMY)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert ...
Inflammation covertly rewires the bone marrow, enabling mutated stem cells to rise and setting the stage for future blood disease.
In the first-line treatment of higher-risk myelodysplastic syndromes (MDS), the combination of venetoclax with azacitidine fell short of the primary endpoint of a reduction in mortality compared with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback